Yahoo
NasdaqCM - Nasdaq Real Time Price USD

CDT Equity Inc. (CDT)

1.1500 0.0000 (0.00%)
As of 11:34:29 AM EDT. Market Open.
Chart Range Bar
Loading chart for CDT
  • Previous Close 1.1500
  • Open 1.0700
  • Bid 0.8928 x 200
  • Ask 1.3800 x 200
  • Day's Range 1.0600 - 1.2500
  • 52 Week Range 0.6710 - 610.0000
  • Volume 1,555,548
  • Avg. Volume 6,908,669
  • Market Cap (intraday) 5.587M
  • Beta (5Y Monthly) 1.41
  • PE Ratio (TTM) --
  • EPS (TTM) -1,177.8900
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

www.cdtequity.com

4

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CDT
96.41%
S&P 500 (^GSPC)
8.43%

1-Year Return

CDT
99.75%
S&P 500 (^GSPC)
21.84%

3-Year Return

CDT
100.00%
S&P 500 (^GSPC)
70.70%

5-Year Return

CDT
100.00%
S&P 500 (^GSPC)
73.97%

Statistics

View More

Valuation Measures

Annual
As of 6/23/2026
  • Market Cap

    5.51M

  • Enterprise Value

    4.78M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    5.16

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -344.95%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -39.22M

  • Diluted EPS (ttm)

    -1,177.8900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.51M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    5.22M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.1500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: